numares announces FDA 510(k) Submission of AXINON System®, a NMR platform for metabolomics-based, AI-driven Diagnostics
24.3.2021 14:00:00 EET | Business Wire | Press release
Leading NMR diagnostics company numares AG today announced that the company made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its AXINON® IVD System, a NMR-platform for AI-driven, metabolomics-based diagnostics. If cleared, AXINON® would become the first NMR-based clinical laboratory system using AI-evaluated metabolic data. Several multi-marker assays for AXINON® will cover numerous unmet medical needs, in order to prevent, diagnose and treat disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005057/en/
numares AXINON® IVD System: The AI-driven AXINON® Software, in combination with advanced NMR technology, refined by numares' proprietary Magnetic Group SignalingTM, allows metabolomics-based precision diagnostics by implementation of various numares' tests, e.g. to identify early kidney rejection in post-transplant surveillance, assess kidney function by improved determination of glomerular filtration rate (GFR) and risk for cardiovascular disease (CVD). (Photo: Business Wire)
The clearance of AXINON® would bring a novel diagnostic approach to clinical laboratories, the combination of several metabolic biomarkers, so-called metabolite constellations, analyzed by advanced nuclear magnetic resonance (NMR) technology and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software.
"This U.S. regulatory filing for its diagnostics platform is an important milestone for numares," said Winton Gibbons, President - US and co-Chief Executive Officer of numares. “After entering into collaborations on joint diagnostics development with analytical instrumentation and solution provider Bruker Corporation in January 2021, and with Mayo Clinic Laboratories in 2019, this FDA submission is the first step in our common endeavor to bring NMR diagnostics into routine clinical use, and make metabolomics-based diagnostics accessible to the patients.”
numares is currently developing multi-marker algorithms for several diagnostic tests on the AXINON® IVD System. These include AXINON® GFRNMR to reliably assess kidney function by improved determination of glomerular filtration rate (GFR). numares expects to submit this test to the FDA also in the first half 2021. The third assay AXINON® renalTX-SCORE® is intended to reliably identify early kidney rejection in post-transplant surveillance, and be submitted to the FDA in 2022. Further multi-marker tests are in development, e.g., for liver disease, cancer detection, and multiple sclerosis.
Dr. Maulik Shah, numares’ Medical Director comments: “AXINON® provides clinical laboratories with a powerful technology that leverages the information-rich metabolome with artificial intelligence to give healthcare professionals new insights into disease diagnosis and management for improved patient outcomes. At the same time, automation capabilities, excellent precision, easy operability will allow easy adaption of the FDA-cleared system by clinical laboratories and will make AXINON® an indispensable routine diagnostic tool in precision medicine.”
“The 510(k) submission of our AXINON® System is an important step and prerequisite to further strengthen commercialization of numares’ products in the United States”, concludes Dr. Volker Pfahlert, co-CEO of numares and chairman of the executive board. “Metabolic disorders are a rapidly increasing problem and major challenge to today’s healthcare systems. Patients will benefit from our approach to consider the patient's metabolome with sophisticated algorithms. Once cleared by the FDA, we believe AXINON® has the potential to meaningfully improve health outcomes and quality of life for millions of patients.”
The AXINON® System consists of AI-based AXINON® Software, ready-to-use AXINON® kits, and an advanced NMR technology, refined by numares’ proprietary Magnetic Group SignalingTM to ensure highly standardized and automated processing of serum or urine samples in high-throughput.
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005057/en/
Contact information
numares
Christiane Proll
Tel.: +49 941 280 949-14
E-Mail:
christiane.proll@numares.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend15.7.2026 09:00:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company previously extended that submission deadline to June 30, 2026, and has now further extended that submission deadline to December 31, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before December 31, 2026 in order to facilitate paym
HY10 Selected Among the First Participants for Visa’s Infinite Private Program14.7.2026 22:46:00 EEST | Press release
HY10, the first financial and lifestyle platform built for globally mobile ultra and high-net-worth individuals, today announced it is among the first businesses selected to participate in Visa's Infinite Private program. Unveiled at the Visa Payments Forum (VPF) in Paris, the launch brings together unlimited-spend payment cards, concierge and lifestyle services into a single integrated platform, powered by Visa's trusted global payments network. The announcement comes as more than 2,000 leaders from banks, fintechs and payment providers gather at Visa Payments Forum to explore the future of commerce and premium financial services. HY10's participation underscores its position at the forefront of premium financial experiences for globally mobile entrepreneurs, investors and families. "Private banking hasn't fundamentally evolved for decades," said Erekle Tokhosashvili, Co-Founder of HY10. "The world's wealthiest individuals are still forced to piece together multiple providers for bank
L&T Technology Services Partners with Anthropic to Deliver AI-Powered Engineering Intelligence for Products and Manufacturing14.7.2026 18:28:00 EEST | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced a partnership with Anthropic to accelerate Engineering Intelligence by integrating Claude models across engineering processes and LTTS’ AI-powered platforms. The collaboration will help LTTS’ enterprise clients redesign how products and software are developed, enabling faster innovation and improved outcomes at scale. Leveraging Claude across the engineering lifecycle and uniting deep engineering expertise, advanced AI and domain knowledge, LTTS’ Engineering Intelligence discipline will enable clients to create greater value. Rather than automating individual tasks, it enables teams to make faster decisions, streamline workflows and continuously improve how products, manufacturing plants and industrial systems are designed, built and maintained. By integrating Claude models into its platforms including AgenticIQ, PlxAI, Ainfonix™, A
Presidio Investors Announces Sale of ElevATE Semiconductor to Diodes Incorporated14.7.2026 17:56:00 EEST | Press release
Presidio Investors (“Presidio”), a lower middle market private equity firm, today announced that it has entered into a definitive agreement to sell ElevATE Semiconductor, Inc. (“ElevATE”) to Diodes Incorporated (Nasdaq: DIOD) in an all-cash transaction valued at $250 million. ElevATE, headquartered in San Diego, California, is a leading fabless designer of low-power, high-density integrated circuits for the automated test equipment (ATE) industry. The sale marks the successful realization of Presidio’s first continuation fund, which was formed in 2023 to extend the firm’s partnership with ElevATE and support the company’s next phase of growth. The acquisition of ElevATE by a leading global semiconductor company validates the strategy behind the continuation vehicle and delivers a strong outcome for the company, its employees, and Presidio’s investors. Presidio first invested in ElevATE in 2018, when the company was a small, founder-led team of analog chip designers serving the ATE mark
Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut14.7.2026 17:30:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition are heading to the 2026 Experimental Aircraft Association (EAA) AirVenture in Oshkosh, Wisconsin. Both aircraft will be on display for the first time at the show alongside a broad lineup of Cessna and Beechcraft aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714774354/en/ Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut “EAA AirVenture is one of the most important opportunities each year for us to connect with customers and the broader aviation community,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Being on the ground in Oshkosh allows us to showcase the breadth of our portfolio. Events like AirVenture also give us valuable face-to-face time to better understand how our customers operate and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom